Previous Columns

Wall Street just declared unrepeatable, ticketed spectacle the only entertainment asset worth paying for, then spent the same week dumping shares in the four companies that already own sold-out stadiums full of it.

A rigorous new trial shows semaglutide slows measurable biological aging in a small cohort, and the real subject is what that finding is about to be used to build.

HBO Max's 122 Emmy nominations arrive as Paramount Skydance finalizes a $110.9 billion purchase, and the timing turns a trophy case into a home appraisal.

ESA's Euclid telescope confirmed 31 ancient quasars this week, and the real fight is whether JWST spectroscopy follow-up on the little red dots will show the earliest supermassive black holes skip stellar evolution entirely.

Netflix pulled 111 Emmy nominations and its lowest US viewership share in over a year in the same week, and the second number is the one it actually believes.

A new Alzheimer's biomarker beats the leading blood test at predicting who will actually get sick, and its patent was licensed to a startup before the paper even printed.

Taylor Swift's wedding assembled the exact studio, label and distribution executives who monetize her, turning a private ceremony into the entertainment industry's most important off-calendar meeting.

NASA's fixed-price rescue of the Swift telescope is less a story about one satellite than a stress test of whether commercial servicing can save aging orbital assets cheaply

Two independent studies this week show muscle strength predicts heart attack risk on its own terms, which is inconvenient timing for an industry that just bet big on shrinking muscle away with weight loss drugs.

The next advance in heart risk prediction is not a new test. It is teaching AI to reread the CT scan you already got for chest pain.

Supergirl's $100 million-plus flop is being read as proof women cannot open a superhero movie, when it is actually proof nobody at DC wants to greenlight the next check before Paramount decides who signs it.

Galaxy Arena's three-year deal with Trip.com is not a venue strategy; it is a distribution concession that hands the audience relationship to a Chinese travel stack and leaves Macau holding the infrastructure bill.

APAC longevity clinics are selling HDL-C readings as cardiovascular safety signals; a population-scale analysis published this week suggests the marker actively misleads at the concentrations these clinics celebrate.

The Recording Academy built a language eligibility rule that functions as a market perimeter, keeping Asian commercial scale out of the general Grammy field.

Beijing's largest antiaging trial runs on a drug conditionally approved for a blood disorder, in a regulatory space where no APAC agency has defined a primary endpoint for aging.

The DOJ's zero-remedy Paramount-WBD clearance consolidates Western content licensing precisely as K-pop's Big Four and Saudi capital build the APAC distribution infrastructure the regulator never examined.

Family-office capital in Singapore and Hong Kong is pricing partial cellular reprogramming at therapeutic timelines no completed Phase 1 human study supports.